Citations for: DrugBank: Cyproterone Acetate
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017 Nov 8. doi: 10.1093/nar/gkx1037

Entry Type
Name
Value
Parent Entry
Physical & Chemical Properties Data Field
Melting Point
BP: About 210 °C
DrugBank, IARC, Toxnet: 200-201 °C
Cyproterone Acetate (API)
Identifiers Data Field
DrugBank Accession Number
DB04839
Cyproterone Acetate (API)
Cyproterone Acetate (API)
Pharmacology Data Field
Elimination Half-Life (t1/2)
Drugbank: 38 h (oral), 96 h (intramuscular)
Toxnet: 43.9 +/- 12.8 h from two 50 mg CPA tablets
Cyproterone Acetate (API)
Pharmacology Data Field
Metabolism
Metabolized by CYP3A4
Cyproterone Acetate (API)
Pharmacology Data Field
Excretion
60% in the bile and 33% through kidneys.
Cyproterone Acetate (API)
Pharmacology Data Field
Enzyme Interactions
Inhibits CYP19A1, CYP2D6 (DrugBank). May inhibit CYP2C8 (Toxnet).
Cyproterone Acetate (API)
Pharmacology Data Field
Indications
Advanced prostate carcinoma, metastatic hormone refractory prostate cancer, paraphilia, severe acne.
Cyproterone Acetate (API)